BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 140 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $82,355 | +16.7% | 11,632 | +16.0% | 0.00% | +33.3% |
Q2 2023 | $70,597 | -15.6% | 10,028 | 0.0% | 0.00% | -25.0% |
Q1 2023 | $83,634 | -36.5% | 10,028 | -12.5% | 0.00% | -33.3% |
Q4 2022 | $131,630 | -5.9% | 11,466 | +3.3% | 0.01% | -14.3% |
Q3 2022 | $139,885 | +19.1% | 11,102 | 0.0% | 0.01% | +40.0% |
Q2 2022 | $117,459 | -34.9% | 11,102 | 0.0% | 0.01% | -16.7% |
Q1 2022 | $180,519 | -72.5% | 11,102 | -76.6% | 0.01% | -33.3% |
Q4 2021 | $656,047 | -3.6% | 47,368 | 0.0% | 0.01% | -10.0% |
Q3 2021 | $680,678 | -17.3% | 47,368 | -9.0% | 0.01% | -16.7% |
Q2 2021 | $823,290 | +68.7% | 52,074 | +8.5% | 0.01% | +71.4% |
Q1 2021 | $488,007 | +27.3% | 47,985 | -6.8% | 0.01% | +16.7% |
Q4 2020 | $383,444 | +107.5% | 51,469 | -4.3% | 0.01% | +100.0% |
Q3 2020 | $184,782 | -23.5% | 53,794 | +6.1% | 0.00% | -25.0% |
Q2 2020 | $241,533 | +138.2% | 50,689 | -0.0% | 0.00% | +100.0% |
Q1 2020 | $101,380 | -41.7% | 50,690 | +0.6% | 0.00% | -33.3% |
Q4 2019 | $173,801 | +64.1% | 50,377 | +36.3% | 0.00% | +50.0% |
Q3 2019 | $105,922 | -24.4% | 36,971 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $140,120 | -53.4% | 36,971 | 0.0% | 0.00% | -60.0% |
Q1 2019 | $300,944 | +0.9% | 36,971 | 0.0% | 0.01% | -16.7% |
Q4 2018 | $298,356 | +8.9% | 36,971 | +3.0% | 0.01% | +20.0% |
Q3 2018 | $273,948 | -99.8% | 35,904 | +14.7% | 0.01% | +66.7% |
Q2 2018 | $179,429,000 | +20.1% | 31,314 | 0.0% | 0.00% | +50.0% |
Q1 2018 | $149,368,000 | +113057.6% | 31,314 | +16.7% | 0.00% | 0.0% |
Q4 2017 | $132,000 | -58.1% | 26,823 | -55.4% | 0.00% | 0.0% |
Q3 2017 | $315,000 | -5.7% | 60,076 | -0.1% | 0.00% | 0.0% |
Q2 2017 | $334,000 | -33.9% | 60,126 | 0.0% | 0.00% | -50.0% |
Q1 2017 | $505,000 | +40.7% | 60,126 | +5.9% | 0.00% | +33.3% |
Q4 2016 | $359,000 | +33.0% | 56,787 | -7.2% | 0.00% | +50.0% |
Q3 2016 | $270,000 | +50.0% | 61,186 | -3.7% | 0.00% | +100.0% |
Q2 2016 | $180,000 | -66.6% | 63,516 | +21.7% | 0.00% | -75.0% |
Q4 2015 | $539,000 | -9.4% | 52,196 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $595,000 | -23.6% | 52,196 | 0.0% | 0.00% | -20.0% |
Q2 2015 | $779,000 | +17.1% | 52,196 | -4.6% | 0.01% | 0.0% |
Q4 2014 | $665,000 | +24.3% | 54,718 | 0.0% | 0.01% | +25.0% |
Q3 2014 | $535,000 | -23.4% | 54,718 | 0.0% | 0.00% | -20.0% |
Q2 2014 | $698,000 | – | 54,718 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |